Compare VLY & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VLY | IKT |
|---|---|---|
| Founded | 1927 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 220.5M |
| IPO Year | 1994 | 2020 |
| Metric | VLY | IKT |
|---|---|---|
| Price | $12.55 | $2.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $14.65 | $5.00 |
| AVG Volume (30 Days) | ★ 6.2M | 388.2K |
| Earning Date | 04-23-2026 | 03-26-2026 |
| Dividend Yield | ★ 3.31% | N/A |
| EPS Growth | 46.38 | ★ 57.76 |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.58 | N/A |
| Revenue Next Year | $8.51 | N/A |
| P/E Ratio | $22.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.64 | $1.33 |
| 52 Week High | $15.20 | $2.61 |
| Indicator | VLY | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 26.74 | 31.78 |
| Support Level | $11.53 | $1.59 |
| Resistance Level | $15.00 | $2.13 |
| Average True Range (ATR) | 0.31 | 0.10 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 1.66 | 16.49 |
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.